1. Home
  2. RVPHW vs MBINM Comparison

RVPHW vs MBINM Comparison

Compare RVPHW & MBINM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPHW
  • MBINM
  • Stock Information
  • Founded
  • RVPHW 2018
  • MBINM N/A
  • Country
  • RVPHW United States
  • MBINM United States
  • Employees
  • RVPHW 14
  • MBINM 663
  • Industry
  • RVPHW Biotechnology: Pharmaceutical Preparations
  • MBINM Major Banks
  • Sector
  • RVPHW Health Care
  • MBINM Finance
  • Exchange
  • RVPHW Nasdaq
  • MBINM Nasdaq
  • Market Cap
  • RVPHW N/A
  • MBINM N/A
  • IPO Year
  • RVPHW N/A
  • MBINM N/A
  • Fundamental
  • Price
  • RVPHW $0.03
  • MBINM N/A
  • Analyst Decision
  • RVPHW
  • MBINM
  • Analyst Count
  • RVPHW 0
  • MBINM 0
  • Target Price
  • RVPHW N/A
  • MBINM N/A
  • AVG Volume (30 Days)
  • RVPHW 22.4K
  • MBINM N/A
  • Earning Date
  • RVPHW 03-14-2025
  • MBINM N/A
  • Dividend Yield
  • RVPHW N/A
  • MBINM N/A
  • EPS Growth
  • RVPHW N/A
  • MBINM N/A
  • EPS
  • RVPHW N/A
  • MBINM N/A
  • Revenue
  • RVPHW N/A
  • MBINM N/A
  • Revenue This Year
  • RVPHW N/A
  • MBINM N/A
  • Revenue Next Year
  • RVPHW N/A
  • MBINM N/A
  • P/E Ratio
  • RVPHW N/A
  • MBINM N/A
  • Revenue Growth
  • RVPHW N/A
  • MBINM N/A
  • 52 Week Low
  • RVPHW $0.13
  • MBINM N/A
  • 52 Week High
  • RVPHW $0.15
  • MBINM N/A
  • Technical
  • Relative Strength Index (RSI)
  • RVPHW N/A
  • MBINM 39.92
  • Support Level
  • RVPHW N/A
  • MBINM $24.80
  • Resistance Level
  • RVPHW N/A
  • MBINM $25.29
  • Average True Range (ATR)
  • RVPHW 0.00
  • MBINM 0.16
  • MACD
  • RVPHW 0.00
  • MBINM -0.01
  • Stochastic Oscillator
  • RVPHW 0.00
  • MBINM 22.50

About RVPHW Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

About MBINM Merchants Bancorp

Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.

Share on Social Networks: